Previous 10 | Next 10 |
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference PR Newswire CARLSBAD, Calif. , Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome t...
Tyra Biosciences (TYRA +14.0%) owner Boxer Capital bought 125,000 shares at $13.12 per share. The transaction was worth $1.6M. This brings his total share holding to ~6.44M shares Form 4 The stock has a market cap of $497.1M. For further details see: Tyra Biosciences surges 14% as owner...
Gainers: Galera Therapeutics (NASDAQ:GRTX) +11%. TFF Pharmaceuticals TFFP +7%. Annexon (NASDAQ:ANNX) +6%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +4%. Tyra Biosciences (NASDAQ:TYRA) +4%. Losers: CalAmp CAMP -14%. Qilian International Holding Group (NASDAQ:QLI) -4%...
The value of IPOs in the first half of this year surpassed mid-pandemic levels. However, since the Fed intends to start tightening its monetary policy later this month and inflation is rising, many recently listed stocks could suffer. Hence, we think it might be best to avoid the recent IPO s...
Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference PR Newswire CARLSBAD, Calif. , Nov. 10, 2021 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to o...
Should Investors Be Buying These Top Health Care Stocks Today? Health care stocks , among other things, could be in focus in the stock market today . Namely, this would be thanks to the Biden administration’s latest COVID-19 vaccine mandate. In detail, U.S. employers ...
Tyra Biosciences (NASDAQ:TYRA): Q3 GAAP EPS of -$0.72 misses by $0.33. Cash and cash equivalents were $312.8 million as of September 30, 2021, as compared to $15.2 million as of December 31, 2020. Press Release For further details see: Tyra Biosciences EPS misses by $0.33
Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights -Successful completion of upsized $198.7 million initial public offering; cash and cash equivalents of $312.8 million as of September 30, 2021- -Nominated 2nd product candidate for clinical developm...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +68%, Pieris Pharmaceuticals (NASDAQ:PIRS) +11%, Molecular Templates (NASDAQ:MTEM) +11%, Paratek Pharmaceuticals (NASDAQ:PRTK) +9%, Capricor Therapeutics CAPR +4%. Losers: Kintara Therapeutics KTRA -19%, Oncon...
News, Short Squeeze, Breakout and More Instantly...
Tyra Biosciences Inc. Company Name:
TYRA Stock Symbol:
OTCMKTS Market:
Tyra Biosciences Inc. Website:
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) PR Newswire - In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein - -TYRA remain...
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights PR Newswire - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 milli...
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors PR Newswire CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnolog...